

EDITORIALS



Timing of Intervention in Aortic Stenosis

Patrizio Lancellotti, M.D., Ph.D., and Mani A. Vannan, M.B., B.S.

Current guidelines require that in patients with severe aortic stenosis, symptoms related to the valvular disease be present for consideration of transcatheter aortic-valve replacement (TAVR) or surgical aortic-valve replacement.^{1,2} In the absence of symptoms, only very severe aortic stenosis is an indication (class IIa) for intervention.¹⁻³

Kang et al.³ now report in the *Journal* the results of a trial involving patients with asymptomatic, very severe aortic stenosis who were randomly assigned to surgical aortic-valve replacement or conservative care (clinical follow-up and observation). Outcomes (death during or within 30 days after surgery [operative mortality] or death from cardiovascular causes; death from any cause; and hospitalization for heart failure) were significantly better among patients who underwent surgical aortic-valve replacement promptly (within approximately 2 months after randomization) than among those who were randomly assigned to the conservative-care group. These benefits started early and persisted over 8 years, and — impressively — the number needed to treat to prevent one death from cardiovascular causes within 4 years was 20 patients.

It is remarkable that the operative mortality among patients in both the early-surgery group and the conservative-care group was zero, and this includes approximately 17% of the patients in the conservative-care group for whom urgent surgical aortic-valve replacement was indicated because of acute cardiac decompensation. The rather small number of deaths from any cause (5 in the early-surgery group and 15 in the conservative-care group) does constitute a limitation of the trial. Nonetheless, taken at face value, these results certainly confirm the unreliability

of symptoms as a guide to the timing of surgery in patients with aortic stenosis, especially in the elderly or when lifestyle adjustments or coexisting medical conditions limit activity or confound symptoms attributable to valvular disease.

However, in interpreting the trial results, it is important to take the patient population into account. First, the populations of patients in recent TAVR trials, as compared with the population in this trial, include patients who are typically approximately two decades older and have clinically significant coexisting medical conditions, and they do not include patients with congenital bicuspid valves. Furthermore, in the trial conducted by Kang et al., the patients had very severe aortic stenosis (defined as an aortic-valve area of ≤ 0.75 cm² with either a peak aortic jet velocity of ≥ 4.5 m per second or a mean transaortic gradient of ≥ 50 mm Hg), and many of these patients would have met the current class IIa criteria for intervention (according to data from Doppler echocardiography and symptoms during exercise testing or the presence of left ventricular systolic dysfunction).

So, although the trial by Kang et al. has certainly emphasized the challenge of ascertaining valve-related symptoms in the real world, direct extension of these results to patients with asymptomatic severe aortic stenosis cannot be made at this time. We will have to await the results of large, randomized studies of early TAVR in patients with asymptomatic severe aortic stenosis for further guidance.⁴ These studies include AVATAR (Aortic Valve Replacement versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis; ClinicalTrials.gov number, NCT02436655), EVOLVED (Early Valve Replacement Guided by

Severe Aortic Stenosis	Disease Consequences or Cardiac Damage			Management Options	
	Hemodynamic Changes	Structural Changes	Symptoms		
	Stage 0–1: Compensated Disease Normal LVFP Abnormal LV relaxation	LVH (LV mass >115 g/m ² in men; >95 g/m ² in women)			Wait for symptoms
Stage 1–2: Subclinical LV Dysfunction Elevated LVFP Moderate-to-severe mitral regurgitation	GLS <15% LVEF <60% Increased cardiac MRI ECV LA volume >34 ml/m ²	Asymptomatic			
Stage 3–4: Decompensated Disease SVI <30 ml/m ² Moderate-to-severe tricuspid regurgitation PSAP ≥60 mm Hg	Cardiac MRI LGE LVEF <50% RV dysfunction (TAPSE <17 mm, tricuspid annular systolic velocity <9.5 cm/sec)	Symptomatic			

Figure 1. An Approach to Staging in Severe Aortic Stenosis.

The consequences of aortic stenosis are characterized by distinct intracardiac hemodynamics and structural abnormalities. The staging approach shown allows for assessment of the risk of aortic stenosis and influences the follow-up plan, timing of interventions, and indications for intervention. The active follow-up strategy involves scheduling frequent follow-up (typically every 3 to 6 months) and may include stress testing to assess for symptoms that may not otherwise be apparent. The timing of surgery (as indicated by the ranges covered by each management option) is likely to be later in the course of disease with the strategies of waiting for the development of symptoms and active follow-up. Markedly elevated levels of B-type natriuretic peptide (BNP) (3 times the upper limit of the normal range corrected for age and sex) typically occur with the development of decompensated disease. Extracellular volume (ECV) is measured with cardiac magnetic resonance imaging (MRI) T1 mapping to estimate diffuse fibrosis. Global longitudinal strain (GLS) is assessed by means of echocardiography. Late gadolinium enhancement (LGE) is used to evaluate replacement fibrosis. LA denotes left atrial, LV left ventricular, LVEF left ventricular ejection fraction, LVFP left ventricular filling pressure, LVH left ventricular hypertrophy, PSAP pulmonary-artery systolic pressure, RV right ventricular, TAPSE tricuspid annular plane systolic excursion, and SVI stroke volume index.

Biomarkers of LV Decompensation in Asymptomatic Patients with Severe AS; NCT03094143), ESTIMATE (Early Surgery for Patients with Asymptomatic Aortic Stenosis; NCT02627391), and EARLY TAVR (Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients with Asymptomatic Severe Aortic Stenosis; NCT03042104). Also, although the excellent surgical outcomes in this trial may speak to the surgical expertise of the centers involved, the findings cannot be extended confidently to centers with less expertise.

The trial by Kang et al. highlights another issue. Although surgical aortic-valve replacement was indicated for approximately 78% of the patients in the “wait and watch” conservative-care group, it is intriguing that 22% of the patients in this group never underwent surgery. Given that urgent surgical aortic-valve replacement was indicated in 17% of the patients and the time to surgery ranged from approximately 9 months to 4 years, this was a heterogeneous population of patients in whom the structural and functional abnormalities of the heart varied or in whom the

valvular disease progressed at varied rates.⁵ The patients in the conservative-care group who did not undergo surgery may have been those who had less cardiac damage or in whom the disease progressed slowly.

This leads to the question of how best to assess risk among patients with aortic stenosis, formulate a follow-up plan, decide on the timing of intervention, and devise a management strategy. Given that there appears to be a continuous increase in risk starting at a mean aortic-valve gradient of approximately 20 mm Hg,⁶ staging aortic stenosis instead of classifying the valvular lesion only according to data from Doppler imaging appears to be the best approach. Staging the disease includes assessing structural abnormalities of the heart, considering other hemodynamic cardiac abnormalities, and assessing the biomarker profile.⁷⁻⁹ This multipronged method integrates assessment of risk-based disease severity and disease progression and permits the formulation of a follow-up and management plan for each patient with aortic stenosis. An approach to staging in severe aortic stenosis is shown in

Figure 1. In a time of rapidly evolving transcatheter-valve therapies, this framework of risk assessment in patients with aortic stenosis is perhaps best achieved in clinics that are dedicated to the care of patients with more than mild valvular disease to maximize the benefit of timely treatment.⁵

Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.

From the University of Liege Hospital, Interdisciplinary Cluster for Applied Genoproteomics Cardiovascular Sciences, Centre Hospitalier Universitaire Sart-Tilman, Liege, Belgium (P.L.); and Piedmont Heart Institute, Marcus Heart Valve Center, Atlanta (M.A.V.).

This editorial was published on November 16, 2019, at NEJM.org.

1. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2017;70:252-89.

2. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017;38:2739-91.

3. Kang D-H, Park S-J, Lee S-A, et al. Early surgery or conservative care for asymptomatic aortic stenosis. *N Engl J Med* 2020; 382:111-9.

4. Everett RJ, Clavel MA, Pibarot P, Dweck MR. Timing of intervention in aortic stenosis: a review of current and future strategies. *Heart* 2018;104:2067-76.

5. Lancellotti P, Magne J, Dulgheru R, et al. Outcomes of patients with asymptomatic aortic stenosis followed up in heart valve clinics. *JAMA Cardiol* 2018;3:1060-8.

6. Strange G, Stewart S, Celermajer D, et al. Poor long-term survival in patients with moderate aortic stenosis. *J Am Coll Cardiol* 2019;74:1851-63.

7. Vannan MA, Pibarot P, Lancellotti P. Aortic stenosis: the emperor's new clothes. *J Am Coll Cardiol* 2019;74:1864-7.

8. Vollema EM, Amanullah MR, Ng ACT, et al. Staging cardiac damage in patients with symptomatic aortic valve stenosis. *J Am Coll Cardiol* 2019;74:538-49.

9. Tastet L, Tribouilloy C, Maréchaux S, et al. Staging cardiac damage in patients with asymptomatic aortic valve stenosis. *J Am Coll Cardiol* 2019;74:550-63.

DOI: 10.1056/NEJMe1914382

Copyright © 2019 Massachusetts Medical Society.

Treatment after TAVR — Discordance and Clinical Implications

Rick A. Nishimura, M.D., and David R. Holmes, Jr., M.D.

Transcatheter aortic-valve replacement (TAVR) has transformed the treatment of severe aortic stenosis. However, questions remain regarding the long-term outcomes of this procedure, including the risk of thromboembolic complications and valve deterioration. It has been recognized that leaflet thrombosis of surgically implanted bioprosthetic valves may result in stenosis and could be reversed by oral anticoagulants.¹ With TAVR, early leaflet thrombosis has been identified by hypoattenuated leaflet thickening and reduced leaflet motion on four-dimensional computed tomographic (CT) imaging in more than 15% of patients and could be a potentially treatable contributor to future adverse events.^{2,3} Although the long-term effects of hypoattenuated leaflet thickening and reduced leaflet motion are still unknown, observational studies have documented resolution of these imaging findings with oral anticoagulants and fewer cases of valve deterioration if oral anticoagulants were given early after implantation.^{2,4}

Whether routine anticoagulation would prevent leaflet thrombosis and ultimately improve clinical outcomes after TAVR was the focus of

GALILEO (Global Study Comparing a Rivaroxaban-based Antithrombotic Strategy to an Antiplatelet-based Strategy after Transcatheter Aortic Valve Replacement to Optimize Clinical Outcomes), now reported in the *Journal*, in which 1644 patients undergoing TAVR were randomly assigned to receive rivaroxaban or conventional dual antiplatelet therapy.^{5,6} It was surprising and disappointing when the trial was terminated early owing to a higher rate of death or first thromboembolic event and a higher rate of bleeding (the primary outcomes) in the rivaroxaban group than in the antiplatelet group, despite a reduction in hypoattenuated leaflet thickening and reduced leaflet motion (in a substudy analysis). This was particularly alarming since nearly every previous randomized trial involving non-vitamin K antagonist direct oral anticoagulants for the treatment or prevention of other diseases had shown either equivalence or superiority to conventional therapy.

What should we as clinicians do with these discordant data (a reduction in evidence of leaflet thrombosis with anticoagulation but poorer clinical outcomes)? First, if we simply accept